Schonfeld Strategic Advisors LLC Buys 3,372 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Schonfeld Strategic Advisors LLC raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 128.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,000 shares of the medical equipment provider's stock after purchasing an additional 3,372 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Lantheus were worth $537,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Lido Advisors LLC bought a new stake in Lantheus in the 4th quarter valued at $1,366,000. Northern Trust Corp lifted its holdings in shares of Lantheus by 11.7% during the 4th quarter. Northern Trust Corp now owns 916,384 shares of the medical equipment provider's stock worth $81,980,000 after acquiring an additional 96,275 shares during the period. Hancock Whitney Corp lifted its holdings in shares of Lantheus by 2.6% during the 4th quarter. Hancock Whitney Corp now owns 18,366 shares of the medical equipment provider's stock worth $1,643,000 after acquiring an additional 471 shares during the period. Penn Capital Management Company LLC bought a new position in shares of Lantheus during the 4th quarter worth about $11,790,000. Finally, RiverPark Advisors LLC lifted its holdings in shares of Lantheus by 493.3% during the 4th quarter. RiverPark Advisors LLC now owns 3,975 shares of the medical equipment provider's stock worth $356,000 after acquiring an additional 3,305 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 0.6%

Shares of NASDAQ:LNTH traded up $0.45 during trading on Friday, hitting $80.23. 240,834 shares of the company's stock were exchanged, compared to its average volume of 978,708. Lantheus Holdings, Inc. has a 1-year low of $75.00 and a 1-year high of $126.89. The firm has a 50-day moving average price of $97.57 and a two-hundred day moving average price of $93.51. The firm has a market cap of $5.49 billion, a P/E ratio of 13.41 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the prior year, the firm earned $1.69 EPS. The firm's quarterly revenue was up .8% compared to the same quarter last year. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last 90 days. 1.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of analyst reports. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial cut their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus has a consensus rating of "Buy" and an average target price of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.